AddLife completes the acquisition of MBA Incorporado S.L, a leading Spanish orthopaedic and trauma surgery business

AddLife has today completed the previously announced acquisition of MBA Incorporado S.L (“MBA”), a leading independent orthopaedic surgery distributor with operations in Spain, Italy and Portugal. In 2021 the company had a turnover of approximately EUR 67 million and an EBITA-margin of approximately 17%. The purchase price for 100 percent of the equity amounted to EUR 111 million cash.

MBA will operate as a separate subgroup and be part of the Medtech business area.

Stockholm, 20 January 2022
AddLife AB (publ)

For further information, please contact:
Martin Almgren, Business Area Manager Medtech and CFO, AddLife AB, +46 (0)702 28 15 45
Kristina Willgård, CEO, AddLife AB, +46 (0)705 10 12 23

Brief overview of MBA
Founded in 1988, MBA is a leading Spanish independent distributor in the field of orthopaedic surgery. The company offers solutions and high-quality products and adds customer value with its high level of clinical expertise and provision of services to public and private customers in Spain, Portugal and Italy. The Group has business operations in ten therapeutic segments, with the main areas being orthopaedic implants for hip, knee, and shoulder reconstructions, as well as products and solutions intended mainly for back surgery and neurosurgery, trauma and anaesthesia.
MBA is expected to generate sales of approximately EUR 67 million in the 2021 financial year, with EBITA of approximately 17 percent. The company has about 285 employees and is based in Gijon, Asturias, Spain.

 
AddLife is an independent European player in Life Science that offers high-quality products, services and consulting to both the private and public sectors. AddLife has about 1,800 employees in around 70 operating subsidiaries, which operate under their own brands. The Group has annual sales of approximately SEK 7.5 billion. AddLife is listed on the NASDAQ Stockholm stock exchange.

This information was issued for publication on 20 January 2022 at 14:30 CET.